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Introduction: The 15q25 region has been associated with lung-
cancer risk and might also be associated with the prognosis of lung 
cancer. This study was conducted to determine the impact of a func-
tional polymorphism in the CHRNA3 gene on chromosome 15q25 in 
the survival of patients with early-stage non–small-cell lung cancer 
(NSCLC).
Methods: Five hundred and eighty-three consecutive patients with 
surgically resected NSCLC were enrolled. The rs6495309C > T poly-
morphism in the promoter of the CHRNA3 gene was investigated. 
The association between genotype and overall survival (oS) and 
disease-free survival (DFS) was analyzed.
Results: Patients with the rs6495309 CT or TT genotype had a 
significantly better oS and DFS than the rs6495309 CC genotype 
(adjusted hazard ratio for oS = 0.56, 95% confidence interval = 
0.41–0.75, p = 0.0001; and adjusted hazard ratio for DFS = 0.61, 
95% confidence interval = 0.48–0.79, p = 0.0001). An association 
between the rs6495309C > T polymorphism and survival outcome 
was demonstrated in smokers and never-smokers, and in squamous-
cell carcinomas and adenocarcinomas.
Conclusion: The CHRNA3 rs6495309C > T polymorphism may 
affect survival in patients with early-stage NSCLC. Analysis of the 
rs6495309C > T polymorphism can help identify patients at high risk 
of a poor disease outcome.
Key Words: CHRNA3, Polymorphism, Non–small-cell lung cancer, 
Survival.
(J Thorac Oncol. 2012;7: 808–814)
Single nucleotide polymorphisms (SNPs) are the most com-mon form of human genetic variation. Several studies have 
demonstrated that some of these SNPs affect the expression 
or activities of enzymes; therefore, they are associated with 
the risk of cancer.1–3 In addition, genetic polymorphisms are 
increasingly studied as potential prognostic factors in a variety 
of cancers including lung cancer.4–7
Recently, genome-wide association studies (GWASs) 
have identified hundreds of genetic variants influencing the 
risk of complex human diseases, including lung cancer.8–10 
In addition, these GWASs have highlighted the significance 
of understanding the diverse molecular pathways underlying 
specific human diseases.9–11 The 15q25 region that contains the 
nicotine acetylcholine receptor  subunit 5 and 3 (CHRNA5 
and CHRNA3) genes and the nicotine acetylcholine receptor b 
subunit 4 (CHRNB4) gene has been identified as a lung-cancer 
susceptibility locus in GWASs conducted in populations of 
European ancestry.12–14 This locus has also been shown to be 
associated with lung-cancer risk in several replication studies 
conducted in diverse populations.15–17 In addition, there is a 
growing body of evidence that nicotinic acetylcholine recep-
tors (nAChRs) are involved in the etiology and progression 
of lung cancer through nicotine dependence and activation of 
downstream signaling networks that promote cell proliferation, 
survival, migration, invasion, and angiogenesis.18–20 Based on 
the biological significance of nAChRs in lung-cancer carcino-
genesis, it is possible that functional genetic variants in the 
15q25 region contribute to the prognosis of lung cancer.
Three SNPs (rs8034191, rs16969968, and rs1051730) 
that map to a region of strong linkage disequilibrium in the 
CHRNA5-CHRNA3-CHRNB4 gene cluster have been reported 
to be strongly associated with the risk of lung cancer in 
Caucasian populations.12–14 However, these three SNPs are 
extremely rare in Asian populations, according to the HapMap 
database. In addition, Wu et al.15 have reported that these 
three SNPs are very rare (minor allele  frequencies < 0.05) 
and are not associated with the risk of lung cancer in Chinese 
populations.15 Interestingly, Wu et al.15 reported that the 
rs6495309C > T polymorphism in the promoter of the CHRNA3 
gene affects the binding ability of the transcriptional factor, 
oct-1, resulting in alteration of the CHRNA3 expression. 
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In addition, Wu et al.15 reported that individuals with higher 
production of the rs6495309C allele for CHRNA3 were at a 
significantly increased risk of lung cancer. Therefore, we eval-
uated the prognostic effect of the rs6495309C > T polymor-




This study included all patients (n = 583) with stage I, 
II, or IIIA (micro-invasive N2) NSCLC, who underwent cura-
tive surgical resection at the Kyungpook National University 
Hospital (KNUH, Daegu, Korea) between December 1997 and 
october 2009. Tumor and corresponding nonmalignant lung-
tissue specimens were provided by the National Biobank of 
Korea, KNUH, which is supported by the Ministry of Health, 
Welfare and Family Affairs. All materials derived from the 
National Biobank were obtained under Institutional Review 
Board approved protocols. All of the patients included in this 
study were ethnic Koreans. None of the patients included 
in this study received chemotherapy or radiotherapy before 
surgery. The histologic types of lung cancers were as fol-
lows: 285 cases (48.9%) were squamous-cell carcinomas 
(SQs); 283 cases (48.5%) were adenocarcinomas (ACs); and 
15 cases (2.6%) were large-cell carcinomas. The pathologic 
staging of the tumors, which was determined according to the 
International System for Staging Lung Cancer,21 was as fol-
lows: 317 patients (54.4%) had stage-I disease; 114 patients 
(19.6%) had stage-II disease; and 152 patients (26.1%) had 
stage-IIIA disease. This study was approved by the Institutional 
Review Board of the KNUH.
Genotype Determination
Genomic DNA was extracted from tissues via protei-
nase K digestion, followed by phenol/chloroform extrac-
tion. The genotype of rs6495309C > T polymorphism was 
determined by polymerase chain reaction and melting-curve 
analysis using fluorescence-labeled hybridization probes 
(LightCycler 480, Roche Diagnostics; Mannheim, Germany). 
For quality control, the genotype analysis was performed 
blind with respect to the subjects. In addition, approximately 
10% of the samples were randomly selected for repeat geno-
typing by a different investigator, and the results were 100% 
concordant. Furthermore, to confirm the genotyping results, 
approximately 10% of the samples were randomly selected to 
be genotyped again by selected polymerase chain reaction-
amplified DNA sequencing, and these results were also 100% 
concordant.
Statistical Analysis
Demographic and clinical information were compared 
across genotypes and stages using chi-square tests for categor-
ical variables. The Hardy–Weinberg equilibrium was tested 
by comparing the observed and expected genotype frequen-
cies using a goodness-of-fit chi-square test. The primary out-
comes used for the present study were overall survival (oS) 
and disease-free survival (DFS). oS was measured from the 
day of surgery until the date of death or to the date of the last 
follow-up. DFS was calculated from the day of surgery until 
recurrence or death from any cause. The survival estimates 
were calculated using the Kaplan–Meier method. The differ-
ences in oS and DFS across different genotypes were com-
pared using the log-rank test. Hazard ratios (HRs) and 95% 
confidence intervals (CIs) were estimated using multivariate 
Cox proportional hazard models, with adjustment for age (≤ 
64 years versus > 64 years), sex (female versus male), smok-
ing status (never-smokers versus ever-smoker), pathologic 
stage (I versus II-IIIA), and adjuvant therapy (yes versus no). 
A homogeneity test was performed to compare the difference 
between genotype-related HRs of the different groups. All 
analyses were performed using Statistical Analysis System for 
Windows, version 9.1 (SAS Institute, Cary, NC).
RESULTS
Patient Characteristics and Clinical Predictors
The clinical and pathologic characteristics of the 
patients and the association with oS and DFS are shown in 
Table 1. There were 198 deaths (34.0%), and the estimated 
5-year oS and DFS for all of the patients was 55% (95% CI 
= 46%–61%) and 39% (95% CI = 37%–51%), respectively. 
The pathologic stage was significantly associated with the 
oS and DFS based on univariate analysis (log-rank p [p
L-R
] < 
0.0001 for oS and DFS). There was no significant difference 
in survival outcomes by age, sex, smoking status, histologic 
subtype, or adjuvant therapy.
Genotype Frequency and Association with 
Clinicopathological Factors
The CHRNA3 rs6495309C > T genotypes were success-
fully obtained from all the patients enrolled, and the frequen-
cies of the genotypes and alleles are listed in Table 2. The 
frequency of the rs6495309C allele among the patients was 
0.551, which was comparable with the Chinese and Japanese 
lung-cancer cases (0.572 and 0.518).15,22. The frequency of the 
rs6495309C allele was significantly associated with smoking 
status (p
trend
 = 0.02); specially, the frequency of the rs6495309C 
allele was significantly higher in ever-smokers (current- and 
former-smokers) than in never-smokers (0.569 versus 0.503, 
p = 0.046). In addition, the rs6495309C allele was more fre-
quent in men and SQs than in women and ACs, respectively 
(p = 0.02, and p = 0.01, respectively).
Effect of the rs6495309C . T Polymorphism  
on Survival Outcomes
The rs6495309C > T polymorphism was significantly 
associated with oS and DFS (under a dominant model for 
the variant T allele; p
L-R 
for oS = 0.0004 and p
L-R 
for DFS = 
0.005; Table 3 and Fig. 1). Based on multivariate analysis, the 
rs6495309 CT or TT genotype exhibited a better oS and DFS 
than the rs6495309 CC genotype (adjusted HR [aHR] for oS 
= 0.56, 95% CI = 0.41–0.75, p = 0.0001; and aHR for DFS = 
0.61, 95% CI = 0.48–0.79, p = 0.0001).
The association of the rs6495309C > T genotypes with the 
survival of the patients was further examined after categorizing 
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the patients by smoking status and tumor histology (Table 4). 
In ever-smokers, the rs6495309C >T genotype was signifi-
cantly associated with oS and DFS (under a dominant model 
for the variant T allele; aHR for oS = 0.59, 95% CI = 0.42–
0.82, p = 0.002; and aHR for DFS = 0.58, 95% CI = 0.44–0.77, 
p = 0.0002). In never-smokers, the rs6495309C > T genotype 
had a significant effect on oS under a dominant model for the T 
allele (aHR = 0.41, 95% CI = 0.20–0.81, p = 0.01). The effects 
of the rs6495309C > T genotype on oS and DFS were not sig-
nificantly different between ever- and never-smokers (p value 
of test for homogeneity [p
H
] for oS = 0.35 and p
H
 for DFS = 
0.54). When categorized by tumor histology, the rs6495309 CT 
or TT genotypes exhibited a significantly better oS and DFS in 
patients with SQs and ACs compared with the rs6495309 CC 
genotype (in patients with SQs, p for oS and DFS = 0.002 and 
0.02, respectively; and in patients with ACs, p for oS and DFS = 
0.05 and 0.01, respectively; p
H
 for oS and DFS = 0.54 and 0.81, 
respectively).
Based on a multivariate survival analysis using a Cox’s 
proportional hazard model, the rs6495309C > T genotype, 
tumor histology (HR for oS for AC/SQ = 1.41, 95% CI = 
1.01–1.97, p = 0.04; HR for DFS for AC/SQ = 1.52, 95% CI 
=1.15–2.00, p = 0.004), and the pathologic stage (HR for oS 
for stage IIIA/II/I = 2.01, 95% CI = 1.43–2.81, p < 0.0001; and 
HR for DFS for stage IIIA/II/I = 2.81, 95% CI = 2.13–3.71, p 
< 0.0001) were independent prognostic factors for the survival 
of patients (Table 5).
DISCUSSION
Several GWASs have mapped a lung-cancer suscepti-
bility locus to chromosome 15q25 containing the CHRNA5, 
CHRNA3, and CHRNB4 genes. In the present study, we deter-
mined the prognostic effect of a functional SNP, rs6495309C 
 T, in the promoter of the CHRNA3 gene in patients with 
surgically resected NSCLC. our study demonstrated that the 
rs6495309  T polymorphism was significantly associated 
with oS and DFS in the patients. In addition, multivariate 
logistic regression analysis revealed that the rs6495309C  
T polymorphism was an independent prognostic factor after 
adjusting for clinicopathologic factors, including pathologic 
TABLE 1. Univariate Analysis for Overall Survival by Demographics, Smoking Status, Histological Type, and 
Pathologic Stage
Variables No. of Cases
Overall Survival Disease-Free Survival
No. of Death (%)a 5Y-OSR (%)b Log-Rank P No. of Event (%)a 5Y-DFSR (%)b Log-Rank P
overall 583 198 (34.0) 55 298 (51.1) 39
Age (yrs)
 ≤64 284 91 (32.0) 59 0.14 140 (49.3) 43 0.18
 <64 299 107 (35.8) 51 158 (52.8) 36
Sex
 Male 427 158 (37.0) 53 0.13 225 (52.7) 39 0.86
 Female 156 40 (25.6) 63 73 (46.8) 38
Smoking status
 Never 155 41 (26.5) 60 0.40 76 (49.0) 33 0.56
 Former 133 46 (34.6) 50 73 (54.9) 32
 Current 295 111 (37.6) 54 149 (50.5) 44
Pack-yearsc
 <20 45 11 (24.4) 65 0.29 20 (44.4) 47 0.85
 20–< 35 140 55 (39.3) 47 73 (52.1) 38
 35–< 50 117 40 (34.2) 55 60 (51.3) 43
 ≥50 126 51 (40.5) 55 69 (54.8) 42
Histological typed
 Squamous-cell ca. 285 97 (34.0) 57 0.86 134 (47.0) 46 0.04
 Adenoca. 283 95 (33.6) 52 154 (54.4) 32
Pathologic stage
 I 317 79 (24.9) 63 < 0.0001 115 (36.3) 52 < 0.0001
 II 114 48 (42.1) 48 74 (64.9) 28
 IIIA 152 71 (46.7) 45 109 (71.7) 22
Adjuvant therapye
 No 131 61 (46.6) 48 0.88 94 (71.8) 28 0.63
 Yes 135 58 (43.0) 43 89 (65.9) 20
a Row percentage.
b Five-year oSR and 5-year DFSR, proportion of survival derived from Kaplan-Meier analysis.
c In never-smokers.
d Fifteen large cell carcinomas were excluded from this analysis.
e  In pathologic stage II-IIIA; 111 cases received chemotherapy, 5 cases received radiotherapy, and 19 cases received both chemotherapy and radiotherapy.
oSR, overall survival rate; DFSR, disease-free survival rate.
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stage. This finding suggests that the chromosome 15q25 
region affects prognosis of patients with lung cancer, and 
modulates susceptibility to lung cancer. Indeed, this is the first 
study to investigate whether or not a genetic variant in the 
15q25 region has a prognostic effect on the survival outcome 
of patients with cancer.
In the present study, the CHRNA3 rs6495309T allele 
was associated with a better survival outcome. This finding is 
biologically plausible, especially in light of the putative func-
tion of this SNP. It has been demonstrated that the rs6495309C 
allele has significantly higher promoter activity compared 
with the rs6495309T allele, resulting in up-regulation of the 
CHRNA3 expression.15 Therefore, it is reasonable to expect that 
patients with a lower-production T allele for CHRNA3 have 
a better survival outcome. In addition, this finding is consis-
tent with the results of a previous study in which the CHRNA3 
TABLE 2. Genotype and Allele Frequencies of rs6495309C > T Polymorphism According to 
Clinicopathologic Factors
Variables No. of Cases
Genotypes, n (%) Allele frequency
CC CT TT P C T P
Age (yrs)
 ≤64 284 82 (28.9) 153 (53.9) 49 (17.3) 0.80 0.558 0.442 0.66
 >64 299 85 (28.4) 156 (52.2) 58 (19.4) 0.545 0.455
Sex
 Male 427 129 (30.2) 230 (53.9) 68 (15.9) 0.04 0.571 0.429 0.02
 Female 156 38 (24.4) 79 (50.6) 39 (25.0) 0.497 0.503
Smoking status
 Never 155 39 (25.2) 78 (50.3) 38 (24.5) 0.14 0.503 0.497 0.08
 Former 133 36 (27.1) 72 (54.1) 25 (18.8) 0.541 0.459
 Current 295 92 (31.2) 159 (53.9) 44 (14.9) 0.581 0.419
 p trend 0.16a 0.51a 0.01a 0.02b 0.02b
Pack-years of smokingc
 <20  45 12 (26.7) 23 (51.1) 10 (22.2) 0.77 0.522 0.478 0.56
 20–<35 140 42 (30.0) 79 (56.4) 19 (13.6) 0.582 0.418
 35–<50 117 39 (33.3) 61 (52.1) 17 (14.5) 0.594 0.406
 ≥50 126 35 (27.8) 68 (54.0) 23 (18.3) 0.548 0.452
Histological typed
 Squamous-cell ca. 285 95 (33.3) 148 (51.9) 42 (14.7) 0.02 0.593 0.407 0.01
 Adenoca. 283 69 (24.4) 152 (53.7) 62 (21.9) 0.512 0.488
Pathologic stage
 I 317 94 (29.7) 166 (52.4) 57 (18.0) 0.98 0.558 0.442 0.88
 II 114 32 (28.1) 60 (52.6) 22 (19.3) 0.544 0.456
 IIIA 152 41 (27.0) 83 (54.6) 28 (18.4) 0.543 0.457
a Cochran-Armitage trend test.
b Mantel–Haenszel linear trend test.
c In never-smokers.
d Fifteen large cell carcinoma cases were excluded for this analysis.
TABLE 3. Overall Survival and Disease-Free Survival According to the XHPNA3 rs6495309C>T Genotypes
Polymorphism/
Genotype
No. of Cases 
(%)a


















 CC 167 (28.6) 70 (41.9) 51 0.002 1.00 93 (55.7) 34 0.007 1.00
 CT 309 (53.0) 93 (30.1) 57 0.53 (0.38–0.72) <0.0001 147 (47.6) 44 0.57 (0.44–0.75) <0.0001
 TT 107 (18.4) 35 (32.7) 54 0.66 (0.44–1.00) 0.05 58 (54.2) 33 0.74 (0.53–1.04) 0.08
 CC 167 (28.6) 70 (41.9) 51 0.0004 1.00 93 (55.7) 34 0.005 1.00
 CT + TT 416 (71.4) 128 (30.8) 56 0.56 (0.41–0.75) 0.0001 205 (49.3) 41 0.61 (0.48–0.79) 0.0001
aColumn percentage.
bRow percentage.
cFive-year survival rate, proportion of survival derived from Kaplan-Meier analysis.
dHRs, 95% CIs and their corresponding P values were calculated using multivariate Cox proportional hazard models, adjusted for age, sex, smoking status, tumor histology, 
pathologic stage and adjuvant therapy.
5Y-oSR, 5-year overall survival rate; 5Y-DFSR, 5-year disease free survival rate; HR, hazard ratio; CI, confidence interval.
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FIGURE 1. Kaplan–Meier plot of overall sur-
vival and disease-free survival by the CHRNA3 
rs6495309C > T genotypes: under a referent 
model, in all patients (A); and under a dominant 
model for the rs6495309T allele: in all patients 
(B), in ever-smokers (C); in never-smokers (D); in 
squamous-cell carcinomas (E); and in adenocarci-
nomas (F). P values, from log-rank test.
813Copyright © 2012 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology  •  Volume  7, Number 5, May 2012 A Functional Polymorphism on 15q25
rs6495309C allele was associated with a significantly increased 
risk of lung cancer as compared with the rs6495309T allele.15 
Moreover, these observations suggest that a lower-production 
genotype for CHRNA3 not only decreases the risk of lung-
cancer development, but also leads to good survival outcome 
in patients with surgically resected early-stage NSCLC.
It has been demonstrated that nAChRs can be triggered 
by nicotine and nicotine-derived nitrosamines in cigarette 
smoke, the most important causative carcinogens for lung AC.23 
Therefore, it can be assumed that genetic variants in the CHRNA 
genes may have a pronounced association with the prognosis of 
lung cancer in smokers, and AC in smokers. In contrast to this 
assumption, however, we observed that the rs6495309C > T poly-
morphism was associated with survival outcome in both never- 
and ever-smokers, and in SQs and ACs. In fact, this finding is 
supported by several reports that showed that genetic variants in 
the CHRNA genes affect lung-cancer risk independent of smok-
ing status13,15,20,22 and the histologic type of lung cancer.13,17,20,22 
Although the mechanism by which SNPs in CHRNA genes con-
tribute to lung carcinogenesis in never-smokers remains to be 
elucidated, other factors, such as food intake and passive smok-
ing, differentiate the mode of contribution of the CHRNA SNPs 
in never-smokers. A recent report pointed out the structural 
similarities between acetylcholine and the carcinogenic nitro-
samine, N-nitrosodiethylamine (DEN), and identified DEN as a 
high-affinity ligand for nAChRs in lung-cancer cells.24 Because 
DEN and similar nitrosamines are contained in numerous foods, 
beverages, and cosmetics,24–26 this family of agents may contrib-
ute to nontobacco-related modulations of nAChRs.20
Several studies have reported that genetic variants in 
the CHRNA5–CHRNA3 region on chromosome 15q25 are 
responsible for tobacco nicotine dependence.14,15,19,27 In agree-
ment with the results of a previous study,15 the frequency of 
the rs6495309C allele was associated with smoking status, 
suggesting an impact of the rs6495309C  T polymorphism 
on nicotine dependence. However, different levels of exposure 
to smoking made no significant difference to genotype and 
allele frequencies.
Validation of genotype–phenotype association studies 
requires replication using an independent data set.28 Although 
TABLE 4. Overall Survival and Disease-Free Survival According to the CHRNA3 Polymorphism Genotypes in Smoking Status, 

















p HR (95% CI)d Pd
Smoking status
 Never
   CC 39 (25.2) 15 (38.5) 53 0.03 1.00 20 (51.3) 19 0.53 1.00
   CT 78 (50.3) 14 (18.0) 71 0.37 (0.17–0.79) 0.01 35 (44.9) 48 0.72 (0.40–1.29) 0.27
   TT 38 (24.5) 12 (31.6) 50 0.47 (0.21–1.07) 0.07 21 (55.3) 23 0.65 (0.35–1.23) 0.19
   CC 39 (25.2) 15 (38.5) 53 0.01 1.00 20 (51.3) 19 0.33 1.00
   CT+TT 116 (74.8) 26 (22.4) 62 0.41 (0.20–0.81) 0.01 56 (48.3) 38 0.70 (0.41–1.19) 0.19
 Ever
   CC 128 (29.9) 55 (43.0) 51 0.03 1.00 73 (57.0) 36 0.01 1.00
   CT 231 (54.0) 79 (34.2) 54 0.57 (0.40–0.81) 0.002 112 (48.5) 44 0.53 (0.39–0.72) <0.0001
   TT 69 (16.1) 23 (33.3) 56 0.66 (0.40–1.08) 0.09 37 (53.6) 39 0.78 (0.52–1.16) 0.22
   CC 128 (29.9) 55 (43.0) 51 0.007 1.00 73 (57.0) 36 0.007 1.00
   CT+TT 300 (70.1) 102 (34.0) 55 0.59 (0.42–0.82) 0.002 149 (49.7) 43 0.58 (0.44–0.77) 0.0002
Histological type
 Squamous-cell ca.
   CC 95 (33.3) 40 (42.1) 49 0.02 1.00 48 (50.5) 42 0.14 1.00
   CT 148 (51.9) 43 (29.1) 60 0.51 (0.33–0.79) 0.003 64 (43.2 48 0.63 (0.43–0.92) 0.02
   TT 42 (14.7) 14 (33.3) 57 0.59 (0.32–1.10) 0.10 22 (52.4) 44 0.73 (0.43–1.23) 0.24
   CC 95 (33.3) 40 (42.1) 49 0.005 1.00 48 (50.5) 42 0.08 1.00
   CT + TT 190 (66.7) 57 (30.0) 60 0.53 (0.35–0.80) 0.002 86 (45.3) 47 0.65 (0.46–0.94) 0.02
 Adenoca.
   CC 69 (24.4) 28 (40.6) 55 0.14 1.00 42 (60.9) 20 0.05 1.00
   CT 152 (53.7) 47 (30.9) 52 0.60 (0.38–0.98) 0.04 78 (51.3) 39 0.57 (0.39–0.84) 0.005
   TT 62 (21.9) 20 (32.3) 51 0.73 (0.40–1.32) 0.30 34 (54.8) 23 0.71 (0.45–1.13) 0.15
   CC 69 (24.4) 28 (40.6) 55 0.05 1.00 42 (60.9) 20 0.02 1.00
   CT+TT 214 (75.6) 67 (31.3) 52 0.64 (0.41–1.00) 0.05 112 (52.3) 35 0.61 (0.43–0.88) 0.01
a Column percentage.
b Row percentage.
c Five-year survival rate, proportion of survival derived from Kaplan-Meier analysis.
d  HRs, 95% CIs and their corresponding P-values were calculated using multivariate Cox proportional hazard models, adjusted for age, sex, smoking status, tumor histology, 
pathologic stage and adjuvant therapy. 5Y-oSR, 5-year overall survival rate; 5Y-DFSR, 5-year disease free survival rate; HR, hazard ratio; CI, confidence interval.
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our finding of a significant association between the CHRNA3 
rs6495309C > T polymorphism and survival outcome was not 
examined in an independent sample, our finding is supported 
by several lines of evidence. This SNP has been reported to 
be associated with the risk of lung cancer.15 Furthermore, our 
finding is biologically plausible in light of the putative func-
tion of the SNP. Therefore, it is unlikely that the association 
occurred by chance.
In conclusion, the CHRNA3 rs6495309C  T SNP was 
shown to be an independent prognostic marker for patients 
with surgically resected NSCLC. Consequently, in addition to 
the pathologic stage, testing for the presence of the CHRNA3 
SNP may help identify patient subgroups at high risk for a 
poor disease outcome, thereby helping to refine therapeutic 
decisions in the treatment of NSCLC. However, because this 
study is the first study to investigate the association between 
CHRNA gene polymorphisms and survival outcomes in can-
cer patients, additional studies are required to confirm the 
findings in diverse ethnic populations.
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TABLE 5. Multivariate Analyses of the Prognostic
Variables
Overall Survival Disease-Free Survival
HR (95% CI) p HR (95% CI) p
rs6495309 (CT + 
TT/CC)
0.56 (0.41–0.75) 0.0001 0.61 (0.48–0.79) 0.0001
Age (>64/≤64 yrs) 1.23 (0.93–1.64) 0.15 1.11 (0.88–1.41) 0.36
Sex (female/male) 0.80 (0.50–1.30) 0.37 0.80 (0.55–1.16) 0.24
Smoking status 
(never/ever)
1.14 (0.88–1.46) 0.32 0.93 (0.76–1.13) 0.45
Histology (AC/SQ) 1.41 (1.01–1.97) 0.04 1.52 (1.15–2.00) 0.004
Pathologic stage 
(II+IIIA/I)
2.01 (1.43–2.81) <0.0001 2.81 (2.13–3.71) <0.0001
Adjuvant therapy 
(Yes/No)
1.05 (0.73–1.51) 0.80 0.92 (0.69–1.24) 0.59
HR, hazard ratio; CI, confidence interval; SQ, squamous-cell carcinoma; AC, 
adenocarcinoma.
